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Genetic Basis for Clinical Response to CTLA-4 Blockade
To the Editor: Snyder et al. (Dec. 4 issue)1 state 
that in patients with melanoma who clinically 
benefit from blockade of cytotoxic T-lymphocyte 
antigen 4 (CTLA-4), the tetrapeptide sequences 
in tumor neoantigens were identical to those in 
known antigenic peptides in pathogens. The au-
thors probably correctly interpret that this coin-
cidence reflects cross-reactivity between cancer 
neoepitopes and relevant epitopes from the mi-
crobial counterparts. However, another explana-
tion is possible. It could be that there was a pos-
itive selection in the thymus for rearranged T-cell 
receptors (TCRs) that preferentially recognize 
pathogen-encoded and major histocompatibility 
complex (MHC)–presented antigenic epitopes. 
Such a feature could have been sculpted by evolu-
tion in TCR variable genes and HLA genes.
More information about these interpretations 
could be gained by knowing the serologic status 
of the patients with respect to the putatively 
cross-reacting microbes. For instance, it would 
be very interesting to ascertain whether the se-
rum samples from patient CR9306 were positive 
for anti–hepatitis D virus antibodies. Negative 
serologic status does not completely exclude 
previous subclinical contact with the infectious 
agent but would certainly argue against cross-
reactivity as an explanation for these observa-
tions.
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The authors reply: The similarities between 
pathogen antigenic peptides and peptide se-
quences in tumor neoantigens in patients with 
melanoma who have a response to anti–CTLA-4 
therapy may indeed arise from several factors. 
TCR cross-reactivity is one possibility, as de-
scribed by Birnbaum et al.1 We agree that an-
other possibility is that positive selection in the 
thymus and sculpting by evolution in TCR and 
HLA genes may have helped to mold the motifs. 
Indeed, Su et al. noted that pathogen-specific 
T cells may be abundant even in unexposed 
adults.2 Thus, in our patients, one can envision 
several possibilities. First, there may be common 
T-cell–recognition motifs present in T cells that 
underlie immunotherapy response regardless of 
exposure. Second, the patients who have a re-
sponse to anti–CTLA-4 therapy may have been 
previously exposed to organisms with antigens 
homologous to tumor neoantigens and may have 
undergone priming. Or third, both of these hy-
potheses may be true. To answer these important 
questions, it will be necessary to characterize the 
serologic status of our patients for potential 
cross-reactivity with microbial antigens.
Important issues need to be addressed mov-
ing forward. At this juncture, the field of cancer 
immunogenomics and the use of high-level ge-
netic analysis to decipher immune-related pheno-
types are accelerating rapidly. Application of such 
efforts may lead to valuable insights in both im-
munology and cancer therapy.
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